Incretin based therapy in the management of steroid induced diabetes mellitus
| dc.contributor.author | El Ghandour, Sarah | |
| dc.contributor.author | Azar, Sami T. | |
| dc.contributor.department | Internal Medicine | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:42:56Z | |
| dc.date.available | 2025-01-24T11:42:56Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | Corticosteroid-induced hyperglycemia is a common medical problem which can cause frequent hospitalizations and therefore relates to an increase in morbidity. Metformin, sulfonylureas, thiazolidinediones and insulin are well known available therapies for the treatment of steroid induced hyperglycemia. Incretin based therapies are a newly developing strategies with a considerable importance in the treatment regimen as well. This review aims at discussing the pathophysiology of steroid induced hyperglycemia in addition to the available therapies used for treatment, focusing on incretin therapies. © 2014 Bentham Science Publishers. | |
| dc.identifier.doi | https://doi.org/10.2174/1573399810666141015102900 | |
| dc.identifier.eid | 2-s2.0-84921925930 | |
| dc.identifier.pmid | 25316147 | |
| dc.identifier.uri | http://hdl.handle.net/10938/30144 | |
| dc.language.iso | en | |
| dc.publisher | Bentham Science Publishers | |
| dc.relation.ispartof | Current Diabetes Reviews | |
| dc.source | Scopus | |
| dc.subject | Corticosteroids | |
| dc.subject | Diabetes mellitus | |
| dc.subject | Hyperglycemia | |
| dc.subject | Incretins | |
| dc.subject | Adrenal cortex hormones | |
| dc.subject | Blood glucose | |
| dc.subject | Diabetes mellitus, type 2 | |
| dc.subject | Dose-response relationship, drug | |
| dc.subject | Hospitalization | |
| dc.subject | Humans | |
| dc.subject | Hypoglycemic agents | |
| dc.subject | Treatment outcome | |
| dc.subject | 2,4 thiazolidinedione derivative | |
| dc.subject | Corticosteroid | |
| dc.subject | Dipeptidyl peptidase iv inhibitor | |
| dc.subject | Glucagon like peptide 1 receptor agonist | |
| dc.subject | Incretin | |
| dc.subject | Insulin | |
| dc.subject | Metformin | |
| dc.subject | Steroid | |
| dc.subject | Sulfonylurea derivative | |
| dc.subject | Antidiabetic agent | |
| dc.subject | Glucose blood level | |
| dc.subject | Article | |
| dc.subject | Corticosteroid induced hyperglycemia | |
| dc.subject | Human | |
| dc.subject | Morbidity | |
| dc.subject | Pathophysiology | |
| dc.subject | Priority journal | |
| dc.subject | Steroid induced diabetes mellitus | |
| dc.subject | Blood | |
| dc.subject | Chemically induced | |
| dc.subject | Dose response | |
| dc.title | Incretin based therapy in the management of steroid induced diabetes mellitus | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1